PT-141 bremelanotide is one of the very few peptides with full FDA approval: it is the active ingredient in Vyleesi, approved in 2019 to treat low sexual desire that causes distress in premenopausal women. Unlike erectile dysfunction drugs, it works in the brain rather than on blood flow. It is effective for some patients, not for all, and it has real side effects that require a medical evaluation first.
What PT-141 Bremelanotide Is
Bremelanotide is a synthetic cyclic peptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH), a natural signaling molecule. It descends from research on Melanotan II, a tanning compound that unexpectedly produced sexual arousal in early studies. Bremelanotide was refined to keep the sexual-function effect while reducing — though not eliminating — the pigmentation effect.
It is a melanocortin receptor agonist, acting mainly at the MC4 receptor in the hypothalamus and related brain regions, with some activity at other melanocortin receptors. That off-target activity explains several of its side effects.
How It Works: Desire Starts in the Brain
Sexual function has several components: desire (interest), arousal (physical and mental readiness) and the vascular response. Medications such as sildenafil and tadalafil improve the vascular step. They do little for someone who has no interest to begin with.
Bremelanotide acts upstream. By activating melanocortin pathways in the brain, it appears to modulate dopamine-related reward and motivation circuits that drive sexual desire. Physical arousal can follow as a downstream effect. The precise mechanism in humans is still being characterized, but the clinical result — in some patients — is a measurable increase in desire and a reduction in the distress associated with low desire.
What the Evidence Shows
In women
Approval was based on two Phase 3 randomized, placebo-controlled trials (the RECONNECT studies) in premenopausal women with hypoactive sexual desire disorder. Compared with placebo, bremelanotide produced statistically significant improvements in desire and reductions in distress related to low desire. Effects were modest on average; some women responded clearly, many did not notice a meaningful difference. A longer open-label extension supported continued benefit and safety in those who chose to keep using it.
In men
Earlier clinical studies explored bremelanotide in men with erectile dysfunction, including some who had not responded to PDE5 inhibitors, and showed improvements in erectile response. It was never approved for men. Use in male patients today is off-label, and the evidence base is much smaller than for women with HSDD.
What is unknown
- Long-term effects of frequent use over many years.
- Efficacy in postmenopausal women, who were not the approved population.
- How it compares head-to-head with addressing underlying causes such as sleep, depression, medication effects or hormone deficiency.
Side Effects and Safety Considerations
The FDA-approved label sets limits on how often bremelanotide can be used and includes specific warnings. The main issues I discuss with patients:
- Nausea. The most common side effect in trials, often worst with the first dose. Some people stop because of it.
- Flushing and headache. Common and usually short-lived.
- Transient blood pressure increase. Blood pressure rises briefly after each dose and heart rate may drop. This is why uncontrolled hypertension and known cardiovascular disease are reasons not to use it.
- Focal hyperpigmentation. Darkening of the face, gums or breasts has been reported, more often with frequent use, and may not fully resolve.
- Drug interactions. Bremelanotide can slow gastric emptying and markedly reduce absorption of oral naltrexone, which matters for anyone taking naltrexone for alcohol or opioid use disorder.
Who May Be a Candidate — and Who Is Not
In my practice, PT-141 bremelanotide is a second-line conversation, not a first one. Low libido is a symptom with many causes, and the evaluation comes before any prescription:
- Medical history and medication review. SSRIs, some blood pressure medications, opioids and hormonal contraceptives can all affect desire.
- Labs. Thyroid function, prolactin, testosterone in men (and sometimes in women), estradiol context, glucose and iron studies. See Lab Testing Before Longevity or Peptide Discussions.
- Sleep, mood and stress. Depression, chronic sleep deprivation and burnout are among the most common contributors.
- Relationship and psychological factors. These are legitimate medical topics and sometimes the most important ones.
For women in perimenopause and beyond, a broader hormone discussion is often more productive; see Hormone Optimization for Women Over 40. For men, low desire may reflect testosterone or upstream reproductive-axis issues, which I discuss in the article on Kisspeptin-10 and the HPG axis.
Branded Versus Compounded
Vyleesi is the FDA-approved, branded product with a consistent formulation and labeled dosing. Compounded bremelanotide also exists. A compounded preparation is not FDA-approved as a finished product, and its quality depends on the pharmacy. If compounding is considered, it should come from a licensed pharmacy on a physician's prescription — never from a "research peptide" website.
Dosing and frequency are individualized and discussed only after an evaluation. The approved label exists for a reason, and I do not recommend improvising around it.
The Bottom Line
PT-141 bremelanotide is a legitimate, FDA-approved option for a specific condition, with randomized trial evidence and a clear safety profile. It helps some patients meaningfully, others not at all, and it is unsuitable for people with uncontrolled blood pressure or cardiovascular disease. At Laeeq M.D., it is considered within a full evaluation of why desire has changed — not offered as a shortcut around that question.
Sources
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — Obstetrics & Gynecology, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder — Obstetrics & Gynecology, 2019. https://pubmed.ncbi.nlm.nih.gov/31599847/
- FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women — FDA announcement (reprinted by BioSpace), 2019. https://www.biospace.com/fda-approves-new-treatment-for-hypoactive-sexual-desire-disorder-in-premenopausal-women
Book a Consultation
If changes in desire or sexual function are affecting your quality of life, a careful medical evaluation is the right place to start. Dr. Laeeq offers a 60-minute consultation, virtually or in person in Reston, VA, to look at causes and discuss whether options such as bremelanotide make sense for you. Book a consultation when you are ready.
This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.
Frequently asked questions
Written by Dr. Laeeq Ahmed Butt, M.D., MBA
Board-certified internist practicing peptide and longevity medicine in Reston, VA, with virtual care in seven states. About Dr. Laeeq